We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BIMZELX (UCB Pharma (division of UCB Australia Pty Ltd))
Product name
BIMZELX
Date registered
Evaluation commenced
Decision date
Approval time
216 (255 working days)
Active ingredients
bimekizumab
Registration type
NCE/NBE
Indication
BIMZELX (solution for injection) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.